To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...

Anti-obesity drugs are only part of the larger treatment plan for most patients. Exercise and nutrition are also keys.

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.

Increasing access to these effective evidence-based treatments would benefit our society as a whole, not just those impacted ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome ...